• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President

    1/18/23 8:00:00 AM ET
    $NRBO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NRBO alert in real time by email

    Experienced Executive Brings Approximately 40 Years of Pharmaceutical, Clinical Development and Operational Experience

    BOSTON, Jan. 18, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases, today announced that it has appointed Joseph Hooker as Interim Chief Executive Officer and President.

    Mr. Hooker's appointment follows Gil Price, M.D.'s decision to retire from his position as President and Chief Executive Officer of NeuroBo. NeuroBo's Board of Directors plans to initiate a candidate search with the assistance of a leading executive search firm to identify Dr. Price's permanent successor.

    "We are at an important stage in the evolution of NeuroBo, so we are pleased to have Joe serve as our President and CEO on an interim basis as we conduct a search for our next CEO," said Andrew I. Koven, Chairman of the NeuroBo Board of Directors. "Joe's experience and demonstrated leadership are an ideal fit for NeuroBo as we move our newly acquired assets, DA-1241 and DA-1726, into the next stages of clinical development and address the other strategies instrumental to NeuroBo's success. We expect to benefit from Joe's combination of clinical, business development and executive expertise, and his diverse experience working with a number of emerging and large biopharmaceutical companies."

    "On behalf of the NeuroBo Board of Directors, I also want to thank Gil for his contributions to NeuroBo during a transformative time in NeuroBo's trajectory, in which we completed the acquisition of rights to DA-1241 and DA-1726, and solidified our financial position by completing a successful $32.3 million financing in November of 2022. Under Joe's leadership, we are highly confident in the NeuroBo team's ability to continue advancing our mission and achieving our long-term goals while executing on NeuroBo's strategic priorities," Mr. Koven concluded.

    Joseph Hooker, Interim CEO and President, stated, "Looking ahead, it is an exciting time for NeuroBo as we continue to advance DA-1241 and DA-1726 through their next stages of clinical development. The acquisition of these two cardiometabolic assets marks a seismic shift for NeuroBo, providing NeuroBo with a highly promising, diversified pipeline with several upcoming value inflection points particularly in the exciting nonalcoholic steatohepatitis (NASH) and obesity space -- areas with enormous market opportunity, and I look forward to collaborating with the Board and NeuroBo's partner, Dong-A ST Co. Ltd., on development of these newly acquired assets. We have an opportunity to make NeuroBo into a leader in development of treatments for NASH, along with obesity and type 2 diabetes, and our focus is to file the Phase 2a IND for DA-1241 NASH indication and preparation for IND filing of DA-1726 an obesity indication."

    "Over the past year, we have developed a clear vision and laid a strong foundation for the future of NeuroBo. I wish to extend my sincere gratitude to my team, our BOD, and our stockholders for their unwavering support during this exciting time," said Dr. Price. 

    About Joseph Hooker: 

    Mr. Hooker has served as an independent consultant and advised on an ad hoc basis for leading management consultancies and various pharmaceutical companies with respect to clinical trials, CROs and program management. Previously, Mr. Hooker was Sr. Director of Clinical Operations/Program Leader Rare Disease, Oncology for X4 Pharmaceuticals, Inc., where he led a cross-functional global program team, pre-clinical through development and commercialization, including strategic planning, oversight, execution of clinical operations and the management of staff. Mr. Hooker earlier served as Director, Program Leadership at Biogen, where he led programs and clinical development for gene therapy, ALS, ophthalmology, rare orphan disease, and CNS. Mr. Hooker also previously served as Senior Director, Clinical Operations at Pierian Bioscience, where he developed and led clinical operations for an oncology device program, and served as Chief Operating Officer of MedAvante-ProPhase and Head, Clinical Operations for Sandoz Biopharmaceuticals, division of Novartis. Mr. Hooker began his pharmaceutical career as Senior Clinical Trial Manager and project leader at DuPont-Merck Pharmaceuticals, and also served at various times in clinical trial management roles at Shire Pharmaceuticals, Cephalon Pharmaceuticals, Quintiles and Novo Nordisk. Mr. Hooker received a BA from Rutgers University and an MBA from Rider University.

    About NeuroBo Pharmaceuticals

    NeuroBo Pharmaceuticals, Inc., is a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases. Its primary therapeutics programs include DA-1241 and DA-1726.  DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucose metabolism, lipid metabolism and weight loss.  DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring, 37-amino acid peptide hormone that is released from the gut after ingestion of a meal, activating both the GLP-1 and glucagon receptors, prompting reduced food intake as well as an increase in energy expenditure, potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists.

    For more information visit: https://www.neurobopharma.com.

    Forward Looking Statements

    Any statements in this press release that are not statements of historical fact constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements regarding the development of NeuroBo's product candidates and the therapeutic potential, timing and nature of clinical trials and potential regulatory approval of NeuroBo's clinical programs and pipeline. Forward-looking statements are usually identified by the use of words, such as "believes," "anticipates," "expects," "intends," "plans," "may," "potential," "will," "could" and similar expressions. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors and risks. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with NeuroBo's ability to execute on its commercial strategy, the success of NeuroBo's new interim CEO and President, the advancement of NeuroBo's drug development pipeline, in particular through clinical development, NeuroBo's expectations regarding hiring a new Chief Executive Officer, NeuroBo's ability to follow the timeline for regulatory submissions and obtain regulatory approvals with respect to the development and commercialization of NeuroBo's current and future product candidates, the ability to realize the benefits of the license agreement with Dong-A, including the impact on future financial and operating results of NeuroBo; the ability to integrate the new product candidates into NeuroBo's business in a timely and cost-efficient manner; the cooperation of NeuroBo's contract manufacturers, clinical study partners and others involved in the development of NeuroBo's current and future product candidates; costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; changes in applicable laws or regulations; effects of changes to NeuroBo's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in NeuroBo's filings with the SEC; and other factors discussed in the "Risk Factors" section of NeuroBo's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022 and NeuroBo's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022. In addition, the forward-looking statements included in this press release represent NeuroBo's views as of the date hereof. NeuroBo anticipates that subsequent events and developments will cause its views to change. However, while NeuroBo may elect to update these forward-looking statements at some point in the future, NeuroBo specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing NeuroBo's views as of any date subsequent to the date hereof.

    Contacts

    Investors & Media:

    Rx Communications Group

    Michael Miller

    +1-917-633-6086 

    [email protected]

     

    Cision View original content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-appoints-joseph-hooker-as-interim-chief-executive-officer-and-president-301724385.html

    SOURCE NeuroBo Pharmaceuticals, Inc.

    Get the next $NRBO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NRBO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRBO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Dong-A St Co., Ltd bought $10,000,003 worth of shares (2,544,530 units at $3.93), increasing direct ownership by 91% to 5,348,229 units (SEC Form 4)

      4/A - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

      7/10/24 11:11:45 AM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Dong-A St Co., Ltd bought $7,964,379 worth of shares (2,544,530 units at $3.13), increasing direct ownership by 91% to 5,348,229 units (SEC Form 4)

      4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

      6/25/24 4:16:11 PM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRBO
    Leadership Updates

    Live Leadership Updates

    See more
    • NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

      Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter of 2024 Anticipate First Patient to be Dosed in the Multiple Ascending Dose Part 2 of the Phase 1 Clinical Trial of DA-1726 in the Third Quarter of 2024 Part 2 of the Phase 2a Trial of DA-1241 for the Treatment of MASH Underway After Enrollment of Part 1 Completed, With Data Expected in the Fourth Quarter of 2024 Cash of $16.0 Million, Expected to Fund the Company Into the Fourth Quarter of 2024 CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focus

      5/9/24 8:01:00 AM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

      Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose First Patient in Second Quarter of 2024 Received Safety Review Committee (SRC) Approval Recommending That the Two-Part Phase 2a Trial of DA-1241 for the Treatment of MASH Continue Without Modification Data from the Phase 2a Trial of DA-1241 Expected in the Second Half of 2024 Cash of $22.4 Million, Expected to Fund the Company Into the Fourth Quarter of 2024 CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseas

      3/28/24 8:01:00 AM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

      CAMBRIDGE, Mass., March 4, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases of cardiometabolic diseases, today announced the appointment of Marshall Woodworth as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective March 1, 2024, following his tenure as Acting Chief Financial Officer since October 27, 2023. "Marshall's decades of experience as a Chief Financial Officer for a variety of pharmaceutical and medical device companies makes him an obvious choice to appoint as a permanent Chief Financial Officer following his tenure in the acting role

      3/4/24 8:01:00 AM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRBO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on NeuroBo Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of NeuroBo Pharmaceuticals with a rating of Buy and set a new price target of $16.00 from $20.00 previously

      2/1/21 6:23:21 AM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRBO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by NeuroBo Pharmaceuticals Inc.

      SC 13G - NeuroBo Pharmaceuticals, Inc. (0001638287) (Subject)

      11/14/24 3:34:00 PM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by NeuroBo Pharmaceuticals Inc.

      SC 13D/A - NeuroBo Pharmaceuticals, Inc. (0001638287) (Subject)

      9/20/24 4:15:21 PM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by NeuroBo Pharmaceuticals Inc.

      SC 13D/A - NeuroBo Pharmaceuticals, Inc. (0001638287) (Subject)

      6/25/24 4:15:10 PM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRBO
    Financials

    Live finance-specific insights

    See more

    $NRBO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update

      BOSTON, April 15, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced financial results for the year ended December 31, 2020 and provided a corporate strategic update. "In December 2020, we significantly expanded our clinical pipeline with the acquisition of ANA Therapeutics and the addition of lead drug candidate, ANA001, a proprietary oral niclosamide formulation, currently in a 60-patient Phase 2/3 trial as a treatment for moderate to severe COVID-19," stated Richard J. Kang, Ph.D., Pres

      4/15/21 4:52:00 PM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & President Kim Hyung Heon covered exercise/tax liability with 2,867 shares, decreasing direct ownership by 4% to 63,799 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      12/2/24 5:31:09 PM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Dong-A St Co., Ltd sold $1,526 worth of shares (407 units at $3.75), decreasing direct ownership by 0.01% to 5,347,792 units (SEC Form 4)

      4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

      9/20/24 4:20:16 PM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & President Kim Hyung Heon covered exercise/tax liability with 11,467 shares, decreasing direct ownership by 15% to 66,666 units (SEC Form 4)

      4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

      8/13/24 4:01:10 PM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRBO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

      New Nasdaq Ticker Symbol will be MTVA CAMBRIDGE, Mass., Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia Inc.," which will be effective on November 29, 2024 (the "Effective Date").  In parallel, the Company's common stock will begin trading on the Nasdaq Stock Market under the new ticker symbol, "MTVA," which is expected to be operative as of the Effective Date. As part of its corporate name change, the company will also launch a new website, metaviatx.com, a

      11/18/24 8:01:00 AM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

      CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November: November 14: Life Science Virtual Investor Forum. Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview on Thursday, November 14, at 1:00 pm ET. Management will also be available for one-on-one meetings during the event. Interested parties who would like to listen to the Company's presentation or request a meeting can do so after registering for the

      11/13/24 8:01:00 AM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Reported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity, Revealing Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics  $21.7 Million in Cash at End of Third Quarter Expected to Fund the Company Into the Third Quarter of 2025 Top-Line Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH Expected in December of 2024 Top-Line Data From the MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in the First Quarter of 2025 Entered into a Joint Research Agreement, Together With Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 CAMBRIDGE, Mass., Nov. 7, 2024 /PRN

      11/7/24 8:01:00 AM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRBO
    SEC Filings

    See more
    • NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MetaVia Inc. (0001638287) (Filer)

      11/29/24 9:10:13 AM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

      11/18/24 8:35:23 AM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by NeuroBo Pharmaceuticals Inc.

      10-Q - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

      11/7/24 4:06:55 PM ET
      $NRBO
      Biotechnology: Pharmaceutical Preparations
      Health Care